maxidex augndropar, dreifa 1 mg/ml
novartis healthcare a/s - dexamethasonum fosfat - augndropar, dreifa - 1 mg/ml
maxitrol augndropar, dreifa
novartis healthcare a/s - neomycinum súlfat; polymyxinum b súlfat; dexamethasonum fosfat - augndropar, dreifa
mydriacyl augndropar, lausn 10 mg/ml
alcon nordic a/s - tropicamidum inn - augndropar, lausn - 10 mg/ml
oculac augndropar, lausn 5 %
alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %
oculac án rotvarnar augndropar, lausn 5 %
alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %
oftaquix augndropar, lausn 5 mg/ml
santen oy* - levofloxacinum hemihýdrat - augndropar, lausn - 5 mg/ml
oftaquix augndropar, lausn í stakskammtaíláti 5 mg/ml
santen oy* - levofloxacinum hemihýdrat - augndropar, lausn í stakskammtaíláti - 5 mg/ml
opnol augndropar, lausn 1 mg/ml
karo pharma ab* - dexamethasonum fosfat - augndropar, lausn - 1 mg/ml
softacort augndropar, lausn í stakskammtaíláti 3,35 mg/ml
laboratoires thea* - hydrocortisonum natríumfosfat - augndropar, lausn í stakskammtaíláti - 3,35 mg/ml
taflotan augndropar, lausn í stakskammtaíláti 15 míkróg/ml
santen oy* - tafluprostum inn - augndropar, lausn í stakskammtaíláti - 15 míkróg/ml